Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication

被引：1

作者：

Bloomgarden, Zachary ^{[1
]}

Handelsman, Yehuda ^{[2
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, Dept Med, New York, NY 10028 USA

[2] Metab Inst Amer, Tarzana, CA USA

来源：

JOURNAL OF DIABETES | 2020年 / 12卷 / 01期

关键词：

KIDNEY-DISEASE; RISK-FACTORS; PREVALENCE; ADULTS;

D O I：

10.1111/1753-0407.13005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：8 / 9

页数：2

共 14 条

[1] Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Afkarian, Maryam
Zelnick, Leila R.
Hall, Yoshio N.
Heagerty, Patrick J.
Tuttle, Katherine
Weiss, Noel S.
de Boer, Ian H.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (06): : 602 - 610
[2] Prevalence and related risk factors of chronic kidney disease among adults in Luxembourg: evidence from the observation of cardiovascular risk factors (ORISCAV-LUX) study
Alkerwi, Ala'a
Sauvageot, Nicolas
El Bahi, Illiasse
Delagardelle, Charles
Beissel, Jean
Noppe, Stephanie
Roderick, Paul J.
Mindell, Jennifer S.
Stranges, Saverio
[J]. BMC NEPHROLOGY, 2017, 18
[3] The kidney and cardiovascular outcome trials
Bloomgarden, Zachary
[J]. JOURNAL OF DIABETES, 2018, 10 (02) : 88 - 89
[4] Sodium-glucose cotransporter 2 inhibitors and renal function
Bloomgarden, Zachary
[J]. JOURNAL OF DIABETES, 2015, 7 (03) : 295 - 298
[5] Federation I. D., 2017, IDF Diabetes Atlas 8th ed, Brussels, V8th
[6] PAIT-survey-Prevalence of albuminuria in patients with diabetes and hypertension in Turkey
Fici, Francesco
Bakir, Elif Ali
Beyaz, Sengul
Makel, Wim
Robles, Nicolas Roberto
[J]. PRIMARY CARE DIABETES, 2018, 12 (06) : 558 - 564
[7] Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014
Kume, Shinji
Araki, Shin-ichi
Ugi, Satoshi
Morino, Katsutaro
Koya, Daisuke
Nishio, Yoshihiko
Haneda, Masakazu
Kashiwagi, Atsunori
Maegawa, Hiroshi
[J]. JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (04) : 1032 - 1040
[8] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V.
Solomon, S. D.
Inzucchi, S. E.
Kober, L.
Kosiborod, M. N.
Martinez, F. A.
Ponikowski, P.
Sabatine, M. S.
Anand, I. S.
Belohlavek, J.
Bohm, M.
Chiang, C. -E.
Chopra, V. K.
de Boer, R. A.
Desai, A. S.
Diez, M.
Drozdz, J.
Dukat, A.
Ge, J.
Howlett, J. G.
Katova, T.
Kitakaze, M.
Ljungman, C. E. A.
Merkely, B.
Nicolau, J. C.
O'Meara, E.
Petrie, M. C.
Vinh, P. N.
Schou, M.
Tereshchenko, S.
Verma, S.
Held, C.
DeMets, D. L.
Docherty, K. F.
Jhund, P. S.
Bengtsson, O.
Sjostrand, M.
Langkilde, A. -M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 1995 - 2008
[9] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Mosenzon, Ofri
Wiviott, Stephen D.
Cahn, Avivit
Rozenberg, Aliza
Yanuv, Ilan
Goodrich, Erica L.
Murphy, Sabina A.
Heerspink, Hiddo J. L.
Zelniker, Thomas A.
Dwyer, Jamie P.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Kato, Eri T.
Gause-Nilson, Ingrid A. M.
Fredriksson, Martin
Johansson, Peter A.
Langkilde, Anna Maria
Sabatine, Marc S.
Raz, Itamar
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08) : 606 - 617
[10] SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Neuen, Brendan L.
Young, Tamara
Heerspink, Hiddo J. L.
Neal, Bruce
Perkovic, Vlado
Billot, Laurent
Mahaffey, Kenneth W.
Charytan, David M.
Wheeler, David C.
Arnott, Clare
Bornpoint, Severine
Levin, Adeera
Jardine, Meg J.
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11) : 845 - 854

← 1 2 →